Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03149029 |
|---|---|
| Brief Title: | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma |
| First Submitted : | May 8, 2017 |
| First Submitted that Met QC Criteria : | May 10, 2017 |
| First Posted : | May 11, 2017 |
| Results First Submitted : | June 8, 2023 |
| Results First Posted with QC Comments : | June 29, 2023 |
| Results First Submitted that Met QC Criteria : | August 28, 2023 |
| Results First Posted : | September 8, 2023 |
| Last Update Submitted that Met QC Criteria : | March 19, 2024 |
| Last Update Posted : | March 21, 2024 |